STAAR Surgical (STAA) reported a fiscal Q4 loss late Tuesday of $0.69 per diluted share, compared with earnings of $0.16 a year earlier.
Analysts polled by FactSet expected a loss of $0.18.
Net sales for the quarter that ended Dec. 27 was $49 million, down from $76.3 million a year earlier.
Analysts surveyed by FactSet expected $77.2 million.
The company expects a fiscal 2025 loss of $1.26 to $1.56 per diluted share. Analysts surveyed by FactSet expect earnings of $0.63.
In fiscal 2025, STAAR plans to manage its working capital and implement appropriate cost-cutting measures. The company intends to lower production output, decrease capital expenditures, and make targeted reductions to operating expenses, which, it said, will "impact headcount and discretionary spend."
STAAR no longer expects to achieve the Vision 2026 Target Sales and Operating Model announced on Sept. 14, 2023.
Shares of the company traded 34% lower in premarket activity Wednesday.
Price: 14.50, Change: -7.38, Percent Change: -33.73
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。